BioNTech is thrilled to announce the successful completion of a monumental funding round, raising an impressive $1.3 billion to further its mission of translating cutting-edge science into effective treatments for patients worldwide. As a global leader in next-generation immunotherapy, BioNTech has assembled a team of over 6,100 dedicated experts leveraging sophisticated computational discovery and advanced therapeutic drug platforms. This substantial investment will accelerate the development of our extensive portfolio of oncology product candidates, which includes innovative mRNA-based therapies, CAR T cells, and a range of protein-based therapeutics. Notably, we are committed to advancing individualized treatments while also making strides in off-the-shelf solutions for better patient access. Additionally, our deep expertise in mRNA vaccine development positions us uniquely to tackle a variety of infectious diseases, developing novel vaccine candidates alongside our cancer therapeutics. This funding will not only enhance our research and development capabilities but also improve our manufacturing processes, ensuring that we remain at the forefront of biopharmaceutical innovation. We are deeply grateful for the support from our investors, which underscores their belief in our transformational approach to healthcare. Together, we are poised to make significant advancements in both oncology and infectious disease treatment, striving to improve survival rates and overall patient outcomes. To stay updated on our journey, visit us at www.BioNTech.com.
BioNTech Secures $1.3 Billion in Funding to Advance Next Generation Immunotherapy Programs
Recently funded 路 $1.3BHealthcare
Get the full BioNTech company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
